ReviewPharmaceuticals (Basel, Switzerland)2025
The Toxicological Profile of Active Pharmaceutical Ingredients-Containing Nanoparticles: Classification, Mechanistic Pathways, and Health Implications.
Review in Pharmaceuticals (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Toxicity of nanostructures in drug delivery applications.Pharmaceutical science advances · 2026Review
- Nanomaterial toxicity and risk assessment integrating functionalization strategies advanced in vitro models and regulatory perspectives.Discover nano · 2026Review
- Antioxidant and antibacterial properties of transition metals and metal oxides for medical uses: mechanisms, design strategies, and biomedical perspectives.Nanoscale advances · 2026Review
- Nanocarrier-Mediated Delivery Systems of Phytochemicals to Enhance and Accelerate Diabetic Wound Healing Processes.Drug design, development and therapy · 2026Review
- Silver Nanoparticles (AgNPs) as a Double-Edged Sword: Synthesis, Factors Affecting, Mechanisms of Toxicity and Anticancer Potentials-An Updated Review till March 2025.Biological trace element research · 2026Review
- Targeting tumor immune evasion: the role of PD-L1 siRNA in advancing cancer immunotherapy.Medical oncology (Northwood, London, England) · 2025Review
- The Potential ofPharmaceuticals (Basel, Switzerland) · 2025Article
- Nanoparticles Based Therapeutic Approaches in Oncogenic Viral Infections: A Review.International journal of nanomedicine · 2025Review
- Antimicrobial and Anti-Biofilm Activity of Dichlorophen-Functionalized Gold Nanoparticles Against Carbapenem-ResistantInternational journal of nanomedicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nanotechnology is the manipulation of matter on an atomic and molecular scale, producing a lot of new substances with properties that are not necessarily easily expected based on present knowledge. Nanotechnology produces substances with unique properties that can be beneficial or harmful depending on their biocompatibility and distribution. Understanding nanomaterial toxicity is essential to ensure their safe application in biological and environmental applications. This review aims to provide a comprehensive overview of nanoparticle toxicity, focusing on their physicochemical properties, mechanisms of cellular uptake, and potential health risks. Key factors influencing toxicity include particle size, shape, concentration, aspect ratio, crystallinity, surface charge, dissolution, and agglomeration. Nanoparticles can induce oxidative stress and inflammation, contributing to adverse effects when inhaled, ingested, or applied to the skin. However, their toxicity may not be limited to just these pathways, as they can also exhibit other toxic properties, such as activation of the apoptotic pathway and mitochondrial damage. By summarizing the current knowledge on these aspects, this article intends to support the development of nanoparticles in a safer way for future applications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.